Intermittent low-dose rapamycin keeps producing the most consistent lifespan signal of any drug tested in mammals. Here is what the 2026 data adds, and how serious longevity protocols are evolving.
Rapamycin remains the single most replicated pro-longevity intervention in mammals. In 2026 the conversation has shifted from "does it work?" to "what is the right intermittent dose for humans who want more healthy years?".
Why rapamycin matters for longevity
Rapamycin inhibits mTORC1, the nutrient-sensing pathway that, when chronically over-activated, accelerates many hallmarks of ageing — impaired autophagy, senescent cell accumulation, immune drift and tissue stiffening. Pulsed inhibition appears to reset these systems without the metabolic side effects seen with daily transplant dosing.
What the 2026 data adds
The PEARL trial follow-up and several investigator-led cohorts now report improvements in lean mass, perceived energy and inflammatory markers at 5–10 mg weekly, with side effects largely limited to transient mouth ulcers and mild lipid changes. Veterinary data from the Dog Aging Project continues to show functional and cardiac benefits.
How serious users are stacking it
Most longevity-literate clinicians pair weekly rapamycin with: a clean baseline (sleep, zone 2, resistance training), targeted supplements such as [spermidine](/supplements/spermidine) and [urolithin A](/supplements/urolithin-a), and metabolic support such as [berberine](/supplements/berberine) when fasting glucose drifts.
The honest caveats
Rapamycin is still off-label for ageing. Dose, cycling and monitoring matter. Anyone considering it should work with a clinician who tracks lipids, glucose, immune markers and oral health, and should read our deeper [rapamycin protocol research](/research) before starting.
Bottom line
In 2026 rapamycin looks less like a fringe biohack and more like a serious geroscience tool — used carefully, intermittently, and as part of a wider longevity stack.
